- Home
- CTMX vs PMVP Comparison
CTMX vs PMVP Comparison
Compare CTMX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- PMVP
- Stock Information
- Founded
- CTMX 2008
- PMVP 2013
- Country
- CTMX United States
- PMVP United States
- Employees
- CTMX N/A
- PMVP N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- CTMX Health Care
- PMVP Health Care
- Exchange
- CTMX Nasdaq
- PMVP Nasdaq
- Market Cap
- CTMX 349.6M
- PMVP 77.4M
- IPO Year
- CTMX 2015
- PMVP 2020
- Fundamental
- Price
- CTMX $1.94
- PMVP $1.16
- Analyst Decision
- CTMX Strong Buy
- PMVP Strong Buy
- Analyst Count
- CTMX 3
- PMVP 1
- Target Price
- CTMX $5.67
- PMVP $5.00
- AVG Volume (30 Days)
- CTMX 3.1M
- PMVP 2.5M
- Earning Date
- CTMX 11-06-2025
- PMVP 11-06-2025
- Dividend Yield
- CTMX N/A
- PMVP N/A
- EPS Growth
- CTMX 263.20
- PMVP N/A
- EPS
- CTMX 0.49
- PMVP N/A
- Revenue
- CTMX $141,100,000.00
- PMVP N/A
- Revenue This Year
- CTMX N/A
- PMVP N/A
- Revenue Next Year
- CTMX N/A
- PMVP N/A
- P/E Ratio
- CTMX $4.09
- PMVP N/A
- Revenue Growth
- CTMX 18.01
- PMVP N/A
- 52 Week Low
- CTMX $0.40
- PMVP $0.81
- 52 Week High
- CTMX $3.10
- PMVP $1.84
- Technical
- Relative Strength Index (RSI)
- CTMX 42.05
- PMVP 36.89
- Support Level
- CTMX $2.04
- PMVP $1.19
- Resistance Level
- CTMX $2.16
- PMVP $1.40
- Average True Range (ATR)
- CTMX 0.12
- PMVP 0.16
- MACD
- CTMX -0.00
- PMVP -0.04
- Stochastic Oscillator
- CTMX 6.58
- PMVP 2.14
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.